Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | TYR | P14679 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | KDR | P35968 | 1/20 | 0.36 |
| ▸ | CD209 | Q9NNX6 | 1/20 | 0.35 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19229002 | 1.00 | ALDH1A1 (0.40) | ALDH1A1THRBCA1CA2CA9 | |
| SCHEMBL16678815 | 0.87 | L3MBTL1 (0.49) | ALDH1A1THRBCA1CA2CA9 | |
| SCHEMBL10388284 | 0.87 | L3MBTL1 (0.49) | ALDH1A1THRBCA1CA2CA9 | |
| SCHEMBL14690893 | 0.87 | L3MBTL1 (0.49) | ALDH1A1THRBCA1CA2CA9 | |
| SCHEMBL20027477 | 0.87 | L3MBTL1 (0.49) | ALDH1A1THRBCA1CA2CA9 | |
| SCHEMBL24943577 | 0.87 | L3MBTL1 (0.49) | ALDH1A1THRBCA1CA2CA9 | |
| SCHEMBL10388282 | 0.87 | L3MBTL1 (0.49) | ALDH1A1THRBCA1CA2CA9 | |
| SCHEMBL14690973 | 0.87 | L3MBTL1 (0.49) | ALDH1A1THRBCA1CA2CA9 | |
| SCHEMBL19770588 | 0.87 | L3MBTL1 (0.49) | ALDH1A1THRBCA1CA2CA9 | |
| SCHEMBL26727391 | 0.87 | L3MBTL1 (0.49) | ALDH1A1THRBCA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021096811-A1 | TUCARESOL DERIVATIVES AND USES THEREOF | BEYONDSPRING PHARMACEUTICALS, INC. (US) | 2021-05-20 | — | — | WO | disclosed |
| US-9868711-B2 | Phenazine-3-one and phenothiazine-3-one derivatives for treatment of oxidative stress disorders | BIOELECTRON TECHNOLOGY CORPORATION (US) | 2018-01-16 | — | — | US | disclosed |
| US-9670170-B2 | Resorufin derivatives for treatment of oxidative stress disorders | BIOELECTRON TECHNOLOGY CORPORATION (US) | 2017-06-06 | — | — | US | disclosed |
| US-20160039775-A1 | RESORUFIN DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISORDERS | PTC THERAPEUTICS, INC. | 2016-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160039775-A1 | RESORUFIN DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISORDERS | TXNRD2, NDUFAB1, NDUFAF1 | ALDH1A1 445/4885THRB 2009/4885CA1 4824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.